Better Health for All

SCHOTT Pharma's core business is the manufacturing of pharmaceutical packaging, including vials, syringes, and ampoules, which are essential for the safe storage and delivery of medications such as vaccines, injectables, biologics, and treatments for diabetes and obesity.

The company's mission is centered on human health, and its entire product portfolio is devoted to enabling the safe administration of medicines. There is no evidence that any of the company's products have negative health outcomes, nor is there any revenue derived from harmful products.

Fair Pay & Worker Respect

The company admitted to violating the National Labor Relations Act (NLRA) in March 2023 by including illegal non-disclosure and non-disparagement clauses in severance agreements for 42 laid-off employees.

A settlement was reached with the NLRB in July 2023, requiring the company to notify current and former employees that these clauses are void. Employee reviews on Glassdoor indicate an average rating of 3.8 out of 5, reflecting a 76% employee engagement score.

Fair Trade & Ethical Sourcing

No quantitative data was provided in the articles for any of the KPIs related to Fair Trade & Ethical Sourcing.

The articles mention general principles, codes of conduct, and sustainability initiatives but lack specific metrics such as the percentage of fair-trade certified spend, audit frequency, number of forced/child labor incidents, traceability coverage, remediation speed, ethical clause coverage, share of high-risk materials, or supplier diversity spend.

Honest & Fair Business

SCHOTT Pharma has a global whistleblowing system, the SCHOTT Integrity Helpline, which has been in place since 2011.

This system offers multiple reporting channels, including email, a web-based system, direct contact with the Compliance Office, and local ombudspersons, and allows for anonymity. The company also has an anti-corruption policy that explicitly rejects corrupt behavior and includes strict rules on gifts, invitations, external intermediaries, donations, and sponsorships. Anti-corruption is a core function of the Compliance Office, which has regional and decentralized representatives. Training on compliance, including anti-corruption, is provided to all employees as part of the Compliance@SCHOTT program. However, there is no evidence regarding the frequency or effectiveness metrics of this training, nor is there information on independent investigation processes for whistleblowing reports.

No War, No Weapons

The company's core business is pharmaceutical packaging and drug delivery systems, and no direct involvement in arms manufacturing, military contracts, or conflict facilitation is evidenced. While the SCHOTT Group, which includes SCHOTT Pharma, is a member of the UN Global Compact,

there is no specific information on the implementation or performance of UN Guiding Principles on Business and Human Rights within SCHOTT Pharma. The company's General Conditions of Sale include a clause requiring customers to ensure products are not supplied to countries prohibiting or limiting imports, but this is a customer obligation, not evidence of the company's own sales compliance or controls. There is no information regarding revenue from defense contracts, R&D in dual-use technologies, sales to embargoed regimes, or investments in peacebuilding initiatives. The company suspended an investment in Russia due to the situation in Ukraine, but this is not a formal divestment policy. No evidence was found for board oversight of defense activities, export end-user certificates, lobbying on arms control, or procurement humanitarian compliance. Similarly, there is no data on human rights due diligence frequency in conflict-affected areas, Arms Trade Treaty compliance, AI military safeguards, dual-use screening, surveillance transparency, ethical red lines, exposure to controversial weapons, war-risk audits, annual conflict partner reviews, defense divestment, conflict minerals, peace tech investment, or procurement from conflict zones.

Planet-Friendly Business

SCHOTT Pharma's climate action roadmap and targets were validated by the Science Based Targets initiative (SBTi) in 2023.

The company aims to achieve climate-neutral operations for Scope 1 and 2 emissions by 2030, with specific targets to reduce absolute Scope 1 and 2 GHG emissions by 46.2% by 2030 and Scope 3 emissions by 27.5% by 2030. Since 2021, SCHOTT Pharma has sourced 100% of its electricity from renewable sources.

Safe & Smart Tech

SCHOTT Pharma's data protection policies state that log files are retained for a maximum of 90 days, and data in the CRM system is retained for a minimum of six years after the last interaction.

This retention period for CRM data is longer than the 2-3 years for 'good data minimization practices', placing it in the -60 tier. The company explicitly states its commitment to complying with applicable data protection laws, including the General Data Protection Regulation (GDPR) and country-specific provisions, and articulates the legal bases for data processing. This aligns with industry-standard compliance, mapping to a 0 tier. Users are granted rights to access, rectify, erase, restrict processing, and revoke consent for data processing, and can manage personalization preferences, which are standard user privacy controls under GDPR, also mapping to a 0 tier.